Undisclosed CEACAM5-MMAE CAPAC / Shasqi - LARVOL DELTA

Pre-targeting with click chemistry facilitates selective MMAE activation in CEACAM5+ tumors: A first-in-class approach to enhance clinical benefit in targeted therapy (AACR 2026) - "It illustrates robust anti-tumor efficacy in multiple tumor models, including large tumors, more representative of the disease in humans, and a favorable tolerability profile. By decoupling the targeting from the payload delivery, pre-targeting with CAPAC minimizes off-target toxicity, enables higher dosing and has the potential to enhance clinical benefit."

Clinical • Gastric Cancer • Oncology • Pancreatic Cancer • CEACAM5

First-in-class click chemistry-based pre-targeting of CEACAM5 tumor antigen selectively activates an MMAE payload at tumors (AACR 2025) - "Moreover, efficacy data indicate a meaningful benefit in cancer CDX models over negative controls. These data support the continued development of CEACAM5 clickable binder in combination with MMAE clickable payload for the treatment of CEACAM5 expressing cancers."

Oncology • CEACAM5

Tumor-selective MMAE activation via CEACAM5 pre-targeting using click chemistry: A first-in-class strategy to enhance clinical benefit in targeted therapy (ESMO 2025) - "By decoupling targeting from payload delivery, this approach minimizes off-target toxicity, enabling higher dosing and the potential for greater clinical benefit. Legal entity responsible for the study Shasqi, Inc."

Clinical • Gastric Cancer • Oncology • Pancreatic Cancer • CEACAM5

CEACAM5 pre-targeting via click chemistry enables tumor-selective MMAE activation: A first-in-class approach to enhance clinical benefit in targeted therapy (AACR-NCI-EORTC 2025) - "It demonstrates robust anti-tumor efficacy in multiple tumor models, including large tumors, and a favorable tolerability profile. By decoupling targeting from payload delivery, this approach minimizes off-target toxicity, enabling higher dosing and the potential for greater clinical benefit."

Clinical • Late-breaking abstract • Gastric Cancer • Oncology • Pancreatic Cancer • CEACAM5